CY1116109T1 - Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος - Google Patents

Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος

Info

Publication number
CY1116109T1
CY1116109T1 CY20151100253T CY151100253T CY1116109T1 CY 1116109 T1 CY1116109 T1 CY 1116109T1 CY 20151100253 T CY20151100253 T CY 20151100253T CY 151100253 T CY151100253 T CY 151100253T CY 1116109 T1 CY1116109 T1 CY 1116109T1
Authority
CY
Cyprus
Prior art keywords
previous packages
micronized
hfa propellant
improved previous
improved
Prior art date
Application number
CY20151100253T
Other languages
Greek (el)
English (en)
Inventor
Rudi Mueller-Walz
Lise-Marie Fueg
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116109(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of CY1116109T1 publication Critical patent/CY1116109T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20151100253T 2009-10-16 2015-03-13 Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος CY1116109T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918149.6A GB0918149D0 (en) 2009-10-16 2009-10-16 Improved medicinal aerosol formulation
EP10768922.6A EP2488158B1 (fr) 2009-10-16 2010-10-15 Formulations medicinales ameliorees en aerosol

Publications (1)

Publication Number Publication Date
CY1116109T1 true CY1116109T1 (el) 2017-02-08

Family

ID=41462450

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100253T CY1116109T1 (el) 2009-10-16 2015-03-13 Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος

Country Status (26)

Country Link
US (3) US20120282189A1 (fr)
EP (3) EP4327807A3 (fr)
JP (5) JP2013507430A (fr)
CN (1) CN102665675B (fr)
AU (1) AU2010305698C9 (fr)
BR (1) BR112012008983A2 (fr)
CA (1) CA2776359C (fr)
CL (1) CL2012000947A1 (fr)
CY (1) CY1116109T1 (fr)
DK (2) DK2881108T3 (fr)
ES (2) ES2533372T3 (fr)
FI (1) FI2881108T3 (fr)
GB (1) GB0918149D0 (fr)
HK (2) HK1173077A1 (fr)
HR (2) HRP20240402T1 (fr)
IL (1) IL219161B (fr)
LT (1) LT2881108T (fr)
MX (1) MX2012004337A (fr)
NZ (1) NZ599901A (fr)
PL (2) PL2881108T3 (fr)
PT (2) PT2488158E (fr)
RS (2) RS53883B1 (fr)
SI (2) SI2881108T1 (fr)
SM (1) SMT201500052B (fr)
WO (1) WO2011045432A1 (fr)
ZA (1) ZA201202452B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234476B2 (en) * 2001-03-30 2006-04-27 Jagotec Ag Medical aerosol formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
FR2420972A1 (fr) 1978-03-31 1979-10-26 Roussel Uclaf Application du peroxyde de thenoyle a titre de medicament
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPS6135815A (ja) 1984-07-28 1986-02-20 Sanshin Seisakusho:Kk 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
ES2193186T3 (es) 1993-12-02 2003-11-01 Abbott Lab Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc.
ATE250439T1 (de) 1995-04-14 2003-10-15 Smithkline Beecham Corp Dosierinhalator für salmeterol
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
JP2001509801A (ja) 1997-01-30 2001-07-24 アルペンストック・ホールディングス・リミテッド 組成物
EP1014943B1 (fr) 1997-02-05 2002-06-19 Jago Research Ag Formulations medicales pour aerosols
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DE59911149D1 (de) * 1998-07-24 2004-12-30 Jago Res Ag Muttenz Medizinische aerosolformulierungen
PT1102579E (pt) * 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP1131059B1 (fr) 1998-11-13 2003-03-05 Jago Research Ag Poudre seche pour inhalation
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002007672A2 (fr) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. Preparation medicinale en aerosol
AU2001278115A1 (en) 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
ATE320242T1 (de) 2000-10-09 2006-04-15 3M Innovative Properties Co Medizinische aerosolzusammensetzung
AU2002234476B2 (en) * 2001-03-30 2006-04-27 Jagotec Ag Medical aerosol formulations
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AR036358A1 (es) 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
ATE465712T1 (de) 2002-03-01 2010-05-15 Chiesi Farma Spa Ultrafeine zusammensetzungen von formoterol
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
JP2005539046A (ja) * 2002-08-29 2005-12-22 シプラ・リミテッド 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物
WO2005004927A2 (fr) 2003-07-12 2005-01-20 Jong-Hun Han Appareil emettant des fragrances destine a etre utilise avec un allume-cigares
NZ545921A (en) 2003-09-19 2009-09-25 Penwest Pharmaceuticals Co Delayed released dosage forms
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
ES2317306T3 (es) * 2004-10-12 2009-04-16 Generics (Uk) Limited Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol.
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
JP2015036045A (ja) * 2013-08-12 2015-02-23 株式会社泉技研 骨質改善のための超音波音響システム及び超音波音響機器の作動方法
JP6135815B1 (ja) 2016-09-29 2017-05-31 東洋インキＳｃホールディングス株式会社 プリント配線板および電子機器

Also Published As

Publication number Publication date
US20140314684A1 (en) 2014-10-23
SI2881108T1 (sl) 2024-04-30
JP2013507430A (ja) 2013-03-04
DK2488158T3 (en) 2015-03-23
ZA201202452B (en) 2013-09-25
US20120282189A1 (en) 2012-11-08
HRP20240402T1 (hr) 2024-06-07
FI2881108T3 (fi) 2024-03-13
DK2881108T3 (da) 2024-03-11
JP2023026517A (ja) 2023-02-24
PT2488158E (pt) 2015-03-16
EP4327807A3 (fr) 2024-04-24
WO2011045432A1 (fr) 2011-04-21
GB0918149D0 (en) 2009-12-02
NZ599901A (en) 2013-08-30
SMT201500052B (it) 2015-05-05
CN102665675A (zh) 2012-09-12
CN102665675B (zh) 2014-03-19
EP4327807A2 (fr) 2024-02-28
JP2017057223A (ja) 2017-03-23
ES2533372T3 (es) 2015-04-09
PT2881108T (pt) 2024-03-13
AU2010305698A1 (en) 2012-04-26
SI2488158T1 (sl) 2015-04-30
JP6568511B2 (ja) 2019-08-28
JP7203701B2 (ja) 2023-01-13
RS65391B1 (sr) 2024-04-30
IL219161A0 (en) 2012-06-28
EP2488158A1 (fr) 2012-08-22
EP2881108B1 (fr) 2023-12-27
HK1211207A1 (en) 2016-05-20
HRP20150174T1 (hr) 2015-05-22
AU2010305698C1 (en) 2013-07-25
PL2881108T3 (pl) 2024-06-17
IL219161B (en) 2019-12-31
JP2015129162A (ja) 2015-07-16
AU2010305698C9 (en) 2014-04-17
JP2019182878A (ja) 2019-10-24
CA2776359A1 (fr) 2011-04-21
PL2488158T3 (pl) 2015-06-30
RS53883B1 (en) 2015-08-31
CA2776359C (fr) 2015-12-08
US10471077B2 (en) 2019-11-12
LT2881108T (lt) 2024-04-10
US20170189423A1 (en) 2017-07-06
MX2012004337A (es) 2012-08-31
AU2010305698B2 (en) 2012-12-20
HK1173077A1 (en) 2013-05-10
BR112012008983A2 (pt) 2016-04-05
ES2973882T3 (es) 2024-06-24
CL2012000947A1 (es) 2012-12-14
EP2881108A1 (fr) 2015-06-10
EP2488158B1 (fr) 2014-12-24

Similar Documents

Publication Publication Date Title
CY1121843T1 (el) Σκευασματα ετανερσεπτης σταθεροποιημενα με ιοντα μαγνησιου
CY1116109T1 (el) Βελτιωμενα φαρμακευτικα σκευασματα αερολυματος
ECSP22046340A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
NI201800133A (es) Nuevos derivados piperidinilo sustituidos con (hetero) arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
JOP20170017B1 (ar) تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
DOP2018000270A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
CL2016003263A1 (es) Composiciones enriquecidas esteroquímicamente para la liberación de ácidos nucléicos.
EA201190092A1 (ru) Композиции с отсроченным высвобождением для перорального применения, содержащие аморфный бардоксолон метил (cddo-me)
MY160734A (en) Besylate salt of a btk inhibitor
CO2020003882A2 (es) Anticuerpo multiespecifico
MY165002A (en) Cylodextrin complexation methods for formulating peptide proteasome inhibitors
CY1115352T1 (el) Μεθοδος παραγωγης ισοτοπου
ECSP14004595A (es) 2-tiopirimidinonas
CY1118593T1 (el) Πρωτοτυπα παραγωγα πυραζινης
UA108858C2 (xx) Похідні ізоксалідину
CO2019011547A2 (es) Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
BR112021022397A2 (pt) Composição
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
CO6450617A2 (es) Produccion de hidrocarburos de isopreno mejorada que usa cianobacterias diseñadas geneticamente
UY33668A (es) ?composiciones de las paredes celulares de ácido ribonucleico bacteriano, y métodos para elaborarlas y usarlas?.
UA112752C2 (uk) Лікарський засіб та метод блокування утворення або посилення знищення білка p24